HUP0104129A2 - 2-Fenil-benzimidazol- és 2-fenil-indol-származékok alkalmazása PARP enzim ihhibitor hatású gyógyszerkészítmények előállítására és új 2-fenil-benzimidazol-származékok - Google Patents

2-Fenil-benzimidazol- és 2-fenil-indol-származékok alkalmazása PARP enzim ihhibitor hatású gyógyszerkészítmények előállítására és új 2-fenil-benzimidazol-származékok

Info

Publication number
HUP0104129A2
HUP0104129A2 HU0104129A HUP0104129A HUP0104129A2 HU P0104129 A2 HUP0104129 A2 HU P0104129A2 HU 0104129 A HU0104129 A HU 0104129A HU P0104129 A HUP0104129 A HU P0104129A HU P0104129 A2 HUP0104129 A2 HU P0104129A2
Authority
HU
Hungary
Prior art keywords
parp
derivatives
new
group
phenylbenzimidazoles
Prior art date
Application number
HU0104129A
Other languages
English (en)
Inventor
Thomas Höger
Michael Kock
Wilfried Lubisch
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0104129A2 publication Critical patent/HUP0104129A2/hu
Publication of HUP0104129A3 publication Critical patent/HUP0104129A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A találmány tárgyát az általános képletű 2-fenil-benzimidazol- és 2-fenil-indolszármazékok - ahol A nitrogénatom vagy metincsoport; R1hidrogénatom vagy alkilcsoport; R2 hidrogénatom, halogénatom,alkilcsoport, nitro-, trifluor-metilcsoport, cianocsoport, -NR21R22, -NHCOR23 és -OR21 általános képletű csoport; R3 -(CH2)q-NR31R32, -(CH2)q-NR33R34 általános képletű csoport, ahol q értéke 0, 1, 2 vagy3; R4 hidrogénatom, alkilcsoport, klór-, bróm-, fluoratom, nitro-,cianocsoport, -NR41R42, -NH-CO-R43 vagy -OR41 általános képletűcsoport - és tautomer, lehetséges enantiomer és diasztereomer formáik,gyógyszer-előanyagaik és fiziológiailag elfogadható sóik, alkalmazásaképezi olyan gyógyszerek előállitására, amelyek poli (ADP-ribóz)-polimeráz (PARP) enzim inhibitoraiként és a PARP enzim patológiásanmegnövekedett aktivitásával kapcsolatos betegségek kezelésérealkalmasak. A találmány tárgyához tarotzik még a fenti képlet alátartozó 3 új 2-fenil-benzimidazolszármazék. Ó
HU0104129A 1998-11-17 1999-11-05 Use of 2-phenylbenzimidazoles and 2-phenylindoles for producing pharmaceutical compositions having parp enzym effect and new 2-phenylbenzimidazol derivatives HUP0104129A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19852816 1998-11-17

Publications (2)

Publication Number Publication Date
HUP0104129A2 true HUP0104129A2 (hu) 2002-05-29
HUP0104129A3 HUP0104129A3 (en) 2002-09-30

Family

ID=7887971

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104129A HUP0104129A3 (en) 1998-11-17 1999-11-05 Use of 2-phenylbenzimidazoles and 2-phenylindoles for producing pharmaceutical compositions having parp enzym effect and new 2-phenylbenzimidazol derivatives

Country Status (30)

Country Link
US (1) US6509365B1 (hu)
EP (1) EP1131301B1 (hu)
JP (2) JP2002529537A (hu)
KR (1) KR20010080474A (hu)
CN (1) CN1331683A (hu)
AR (1) AR021297A1 (hu)
AT (1) ATE302758T1 (hu)
AU (1) AU755694B2 (hu)
BG (1) BG105550A (hu)
BR (1) BR9915381A (hu)
CA (1) CA2350734C (hu)
CO (1) CO5140115A1 (hu)
CZ (1) CZ20011724A3 (hu)
DE (1) DE59912473D1 (hu)
DK (1) DK1131301T3 (hu)
ES (1) ES2247867T3 (hu)
HK (1) HK1041694A1 (hu)
HR (1) HRP20010451A2 (hu)
HU (1) HUP0104129A3 (hu)
ID (1) ID28846A (hu)
IL (1) IL143102A0 (hu)
NO (1) NO20012419L (hu)
PL (1) PL347684A1 (hu)
RU (1) RU2001116581A (hu)
SI (1) SI1131301T1 (hu)
SK (1) SK6742001A3 (hu)
TR (1) TR200101400T2 (hu)
TW (1) TW460466B (hu)
WO (1) WO2000029384A1 (hu)
ZA (1) ZA200103834B (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
TR200200972T2 (tr) 1998-11-03 2002-07-22 Basf Aktiengesellschaft İkameli 2-fenilbenzimidazoller, üretimleri ve kullanımları
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
CA2441177A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
US7786344B2 (en) 2002-07-26 2010-08-31 Basf Plant Science Gmbh Selection method
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004065370A1 (en) * 2003-01-23 2004-08-05 Crystalgenomics, Inc. Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
EP2045327B8 (en) 2005-03-08 2012-03-14 BASF Plant Science GmbH Expression enhancing intron sequences
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
ATE536349T1 (de) * 2005-09-29 2011-12-15 Abbott Lab In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CN101309908A (zh) 2005-11-15 2008-11-19 艾博特公司 作为有效parp抑制剂的取代的1h-苯并咪唑-4-甲酰胺化合物
US20090275619A1 (en) * 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
ES2385849T3 (es) * 2006-05-02 2012-08-01 Abbott Laboratories Las 1H-bencimidazol-4-carboxamidas substituidas son potentes inhibidores de la PARP
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
RU2495035C2 (ru) 2008-01-08 2013-10-10 Мерк Шарп Энд Домэ Лтд Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
JP5944320B2 (ja) 2009-11-27 2016-07-05 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー 最適化エンドヌクレアーゼおよびその使用
AU2010325564A1 (en) 2009-11-27 2012-07-12 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
WO2011107504A1 (de) 2010-03-04 2011-09-09 Bayer Cropscience Ag Fluoralkyl- substituierte 2 -amidobenzimidazole und deren verwendung zur steigerung der stresstoleranz in pflanzen
EP2561759A1 (en) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
CN104780764A (zh) * 2012-09-05 2015-07-15 拜尔农作物科学股份公司 取代的2-酰氨基苯并咪唑、2-酰氨基苯并噁唑和2-酰氨基苯并噻唑或其盐作为活性物质对抗非生物植物胁迫的用途
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3522230A1 (de) * 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
AU714873B2 (en) * 1995-08-02 2000-01-13 Newcastle University Ventures Limited Benzimidazole compounds
WO1998006703A1 (en) * 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists

Also Published As

Publication number Publication date
ID28846A (id) 2001-07-05
KR20010080474A (ko) 2001-08-22
HUP0104129A3 (en) 2002-09-30
IL143102A0 (en) 2002-04-21
DK1131301T3 (da) 2006-01-09
ZA200103834B (en) 2002-05-13
SI1131301T1 (sl) 2006-02-28
CZ20011724A3 (cs) 2001-08-15
CO5140115A1 (es) 2002-03-22
AU1379800A (en) 2000-06-05
CA2350734C (en) 2006-10-10
EP1131301A1 (de) 2001-09-12
RU2001116581A (ru) 2004-02-20
PL347684A1 (en) 2002-04-22
ES2247867T3 (es) 2006-03-01
DE59912473D1 (de) 2005-09-29
BG105550A (en) 2001-12-31
WO2000029384A1 (de) 2000-05-25
BR9915381A (pt) 2001-08-14
NO20012419L (no) 2001-07-12
TW460466B (en) 2001-10-21
TR200101400T2 (tr) 2001-11-21
NO20012419D0 (no) 2001-05-16
HK1041694A1 (zh) 2002-07-19
JP2009120609A (ja) 2009-06-04
SK6742001A3 (en) 2001-12-03
JP2002529537A (ja) 2002-09-10
US6509365B1 (en) 2003-01-21
HRP20010451A2 (en) 2003-04-30
EP1131301B1 (de) 2005-08-24
ATE302758T1 (de) 2005-09-15
AR021297A1 (es) 2002-07-03
AU755694B2 (en) 2002-12-19
CN1331683A (zh) 2002-01-16
CA2350734A1 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
HUP0104129A2 (hu) 2-Fenil-benzimidazol- és 2-fenil-indol-származékok alkalmazása PARP enzim ihhibitor hatású gyógyszerkészítmények előállítására és új 2-fenil-benzimidazol-származékok
HUP0201832A2 (hu) Kinazolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárások előállításukra
HUP0301236A2 (hu) Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként
HUP0203548A2 (hu) Új spirooxindolszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
HUP0402504A2 (hu) Purinszármazékok, mint purinerg receptor antagonisták
HUP0402150A2 (hu) A CB1 jelzésű kannabinoid receptorra nézve agonista, parciális agonista vagy antagonista hatású 1H-imidazol-származékok, eljárás az előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
HUP0002347A2 (hu) Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására
HUP0200312A2 (hu) Szubsztituált 2-fenil-benzimidazolok, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk
PE20030746A1 (es) DERIVADOS DE PIRIDO [2,1-a] ISOQUINOLINA
BG105596A (en) Substituted benzimidazoles and their use as parp inhibitors
BR0007424A (pt) Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto
MA26870A1 (fr) Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4
HUP0300427A2 (hu) [(Hidroxi-fenil)-4-piperidinilidén-metil]-benzamid-származékok fájdalom kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0203448A2 (hu) Monoamin újrafelvétel inhibitorként alkalmazható új biaril-éter származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0203225A2 (hu) Benzodiazepinszármazékok, előállításuk és alkalmazásuk
TR200100659T2 (tr) 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
HUP0200859A2 (hu) Cikloalkil-szubsztituált benzimidazolok, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk
RU95109927A (ru) Производные 5-арилиндола и их применение в качестве агонистов серотонина (5-ht*00i)
HUP0401086A2 (hu) 4-[(Fenil-piperazinil)-metil]-benzamid-származékok és alkalmazásuk fájdalom, szorongás vagy gasztrointesztinális zavarok kezelésére szolgáló gyógyszerkészítmények előállítására és eljárás a vegyületek előállítására
RU2002103302A (ru) Производные N-(Индолкарбонил)пиперазина
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO306236B1 (no) Anvendelse av vasodilaterende forbindelse til fremstilling av antiiskemisk medikament
MY115278A (en) Acylaminoindole derivatives
DE60014339T8 (de) Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren